Elf3 Drives β-catenin Transactivation and Associates with Poor Prognosis in Colorectal Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2014 May 31

PMID 24874735

Citations 45

Authors

J-L Wang

Z-F Chen

H-M Chen

M-Y Wang

X Kong

Y-C Wang

T-T Sun

J Hong

W Zou

J Xu

J-Y Fang

Affiliations

Soon will be listed here.

Abstract

Aberrant regulation of the Wnt/β-catenin pathway plays important roles in colorectal carcinogenesis, with over 90% of cases of sporadic colon cancer featuring β-catenin accumulation. While ubiquitination-mediated degradation is widely accepted as a major route for β-catenin protein turnover, little is known about the regulation of β-catenin in transcriptional level. Here we show that Elf3, a member of the E-twenty-six family of transcription factors, drives β-catenin transactivation and associates with poor survival of colorectal cancer (CRC) patients. We first found recurrent amplification and upregulation of Elf3 in CRC tissues, and further Gene Set Enrichment Analysis identified significant association between Elf3 expression and activity of WNT/β-catenin pathway. Chromatin immunoprecipitation and electrophoretic mobility shift assay consistently revealed that Elf3 binds to and transactivates β-catenin promoter. Ectopic expression of Elf3 induces accumulation of β-catenin in both nucleus and cytoplasm, causing subsequent upregulation of several effector genes including c-Myc, VEGF, CCND1, MMP-7 and c-Jun. Suppressing Elf3 in CRC cells attenuates β-catenin signaling and decreases cell proliferation, migration and survival. Targeting Elf3 in xenograft tumors suppressed tumor progression in vivo. Taken together, our data identify Elf3 as a pivotal driver for β-catenin signaling in CRC, and highlight potential prognostic and therapeutic significance of Elf3 in CRC.

Citing Articles

Multi-omics integration analysis of the amino-acid metabolism-related genes identifies putatively causal variants of ACCS associated with hepatitis B virus-related hepatocellular carcinoma survival.

Wei X, Yang X, Duan S, Lin Q, Qiu M, Wen Q BMC Cancer. 2025; 25(1):284.

PMID: 39966747 PMC: 11834470. DOI: 10.1186/s12885-025-13604-3.

Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management.

Alnakli A, Mohamedali A, Heng B, Chan C, Shin J, Solomon M BJC Rep. 2024; 2(1):13.

PMID: 39516345 PMC: 11523985. DOI: 10.1038/s44276-024-00043-z.

Switch of ELF3 and ATF4 transcriptional axis programs the amino acid insufficiency-linked epithelial-to-mesenchymal transition.

Lin J, Hou L, Zhao X, Zhong J, Lv Y, Jiang X Mol Ther. 2024; 32(6):1956-1969.

PMID: 38627967 PMC: 11184330. DOI: 10.1016/j.ymthe.2024.04.025.

Progesterone-mediated remodeling of the maternal-fetal interface by a PGRMC1-dependent mechanism.

Wang F, Ferreira L, Mazzanti A, Yu H, Gu B, Meissner T J Reprod Immunol. 2024; 163:104244.

PMID: 38555747 PMC: 11151737. DOI: 10.1016/j.jri.2024.104244.

Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review).

Shao C, Han Y, Huang Y, Zhang Z, Gong T, Zhang Y Int J Oncol. 2023; 64(2).

PMID: 38131226 PMC: 10783943. DOI: 10.3892/ijo.2023.5605.

References

Qiang Y, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B . Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood. 2009; 113(18):4319-30. PMC: 2676089. DOI: 10.1182/blood-2008-08-174300. View

Xu J, Wang J, Xu B, Ge H, Zhou X, Fang J . Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria. Mol Cancer Ther. 2013; 12(5):717-24. DOI: 10.1158/1535-7163.MCT-12-1016-T. View

Alexander M, Kawahara G, Motohashi N, Casar J, Eisenberg I, Myers J . MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. Cell Death Differ. 2013; 20(9):1194-208. PMC: 3741500. DOI: 10.1038/cdd.2013.62. View

Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W . Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature. 2011; 480(7375):118-22. PMC: 3235705. DOI: 10.1038/nature10598. View

Cawthorn W, Heyd F, Hegyi K, Sethi J . Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ. 2007; 14(7):1361-73. PMC: 4303765. DOI: 10.1038/sj.cdd.4402127. View

Shan L, Li X, Liu L, Ding X, Wang Q, Zheng Y . GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation. Oncogene. 2013; 33(24):3205-16. DOI: 10.1038/onc.2013.270. View

Xu J, Reumers J, Couceiro J, De Smet F, Gallardo R, Rudyak S . Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011; 7(5):285-95. DOI: 10.1038/nchembio.546. View

Mathiasen D, Egebjerg C, Andersen S, Rafn B, Puustinen P, Khanna A . Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene. 2011; 31(3):390-401. DOI: 10.1038/onc.2011.230. View

Sheffer M, Bacolod M, Zuk O, Giardina S, Pincas H, Barany F . Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009; 106(17):7131-6. PMC: 2678450. DOI: 10.1073/pnas.0902232106. View

10.

Ciznadija D, Tothill R, Waterman M, Zhao L, Huynh D, Yu R . Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling. Cell Death Differ. 2009; 16(11):1530-8. DOI: 10.1038/cdd.2009.94. View

11.

Bandapalli O, Dihlmann S, Helwa R, Macher-Goeppinger S, Weitz J, Schirmacher P . Transcriptional activation of the beta-catenin gene at the invasion front of colorectal liver metastases. J Pathol. 2009; 218(3):370-9. DOI: 10.1002/path.2539. View

12.

Kaplan M, Wang X, Xu H, Dosik M . Partially unspliced and fully spliced ELF3 mRNA, including a new Alu element in human breast cancer. Breast Cancer Res Treat. 2004; 83(2):171-87. DOI: 10.1023/B:BREA.0000010710.51614.2d. View

13.

Nakarai C, Osawa K, Matsubara N, Ikeuchi H, Yamano T, Okamura S . Significance of ELF3 mRNA expression for detection of lymph node metastases of colorectal cancer. Anticancer Res. 2012; 32(9):3753-8. View

14.

Xu J, Qian J, Hu Y, Wang J, Zhou X, Chen H . Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. Sci Rep. 2014; 4:4223. PMC: 3936234. DOI: 10.1038/srep04223. View

15.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

16.

Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani R . Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012; 72(6):1547-56. PMC: 3571091. DOI: 10.1158/0008-5472.CAN-11-3222. View

17.

Liu G, Jiang S, Wang C, Jiang W, Liu Z, Liu C . Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. Hepatology. 2012; 55(6):1830-9. DOI: 10.1002/hep.25564. View

18.

Kong X, Qian J, Chen L, Wang Y, Wang J, Chen H . Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J Natl Cancer Inst. 2013; 105(22):1738-49. PMC: 4042874. DOI: 10.1093/jnci/djt271. View

19.

Haupt S, Gamell C, Wolyniec K, Haupt Y . Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. Cell Death Differ. 2013; 20(7):852-4. PMC: 3679466. DOI: 10.1038/cdd.2013.51. View

20.

Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J . Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013; 105(24):1907-11. PMC: 3866154. DOI: 10.1093/jnci/djt300. View